Cancer Genetics and Epigenetics 2024, Vol.12, No.4, 223-233 http://medscipublisher.com/index.php/cge 232 Carlo M., Hakimi A., Stewart G., Bratslavsky G., Brugarolas J., Chen Y., Linehan W., Maher E., Merino M., Offit K., Reuter V., Shuch B., and Coleman J., 2019, Familial kidney cancer: implications of new syndromes and molecular insights, European urology, 76(6): 754-764. https://doi.org/10.1016/j.eururo.2019.06.015 Coppin L., Plouvier P., Crépin M., Jourdain A., Yahya E., Richard S., Paillerets B., Cardot-Bauters C., Lejeune S., Leclerc J., and Pigny P., 2019, Optimization of next-generation sequencing technologies for von Hippel Lindau (VHL) mosaic mutation detection and development of confirmation methods, The Journal of Molecular Diagnostics, 21(3): 462-470. https://doi.org/10.1016/j.jmoldx.2019.01.005 Corrò C., Hejhal T., Poyet C., Sulser T., Hermanns T., Winder T., Prager G., Wild P., Frew I., Moch H., and Rechsteiner M., 2017, Detecting circulating tumor DNA in renal cancer: an open challenge, Experimental and Molecular Pathology, 102(2): 255-261. https://doi.org/10.1016/j.yexmp.2017.02.009 Cowey C., and Rathmell W.K., 2009, VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy, Current Oncology Reports, 11: 94-101. https://doi.org/10.1007/s11912-009-0015-5 Dizman N., Philip E., and Pal S.K., 2020, Genomic profiling in renal cell carcinoma, Nature Reviews Nephrology, 16(8): 435-451. https://doi.org/10.1038/s41581-020-0301-x Gossage L., Eisen T., and Maher E.R., 2015, VHL, the story of a tumour suppressor gene, Nature Reviews Cancer, 15(1): 55-64. https://doi.org/10.1038/nrc3844 Herman J., Latif F., Weng Y., Lerman M., Zbar B., Liu S., Samid D., Duan D., Gnarra J., and Linehan W.M., 1994, Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma, Proceedings of the National Academy of Sciences, 91(21): 9700-9704. https://doi.org/10.1073/pnas.91.21.9700 Hsieh J., Purdue M., Signoretti S., Swanton C., Albiges L., Schmidinger M., Heng D., Larkin J., and Ficarra V., 2017, Renal cell carcinoma, Nature Reviews Disease Primers, 3(1): 1-19. https://doi.org/10.1038/nrdp.2017.9 Kim H., Kim J., Jang H., Han B., and Zang D.Y., 2018, Clinicopathologic significance of VHL gene alteration in clear-cell renal cell carcinoma: an updated meta-analysis and review, International Journal of Molecular Sciences, 19(9): 2529. https://doi.org/10.3390/ijms19092529 Kim H., Shim B., Lee S., Lee J., Lee H., and Kim I.H., 2021, Loss of von Hippel-Lindau (VHL) tumor suppressor gene function: VHL-HIF pathway and advances in treatments for metastatic renal cell carcinoma (RCC), International Journal of Molecular Sciences, 22(18): 9795. https://doi.org/10.3390/ijms22189795 Kim W., and Kaelin W.G., 2004, Role of VHL gene mutation in human cancer, Journal of Clinical Oncology, 22(24): 4991-5004. https://doi.org/10.1200/JCO.2004.05.061 Kurban G., Gallie B., Leveridge M., Evans A., Rushlow D., Matevski D., Gupta R., Finelli A., and Jewett M.A., 2012, Needle core biopsies provide ample material for genomic and proteomic studies of kidney cancer: observations on DNA, RNA, protein extractions and VHL mutation detection, Pathology-Research and Practice, 208(1): 22-31. https://doi.org/10.1016/j.prp.2011.11.001 Lin F., Shi J., Liu H., Zhang J., Zhang P., Wang H., Yang X., and Schuerch C., 2008, Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus, American Journal of Clinical Pathology, 129(4): 592-605. https://doi.org/10.1309/Q0FLUXFJ4FTTW1XR Mazumder S., Higgins P., and Samarakoon R., 2023, Downstream targets of VHL/HIF-α signaling in renal clear cell carcinoma progression: mechanisms and therapeutic relevance, Cancers, 15(4): 1316. https://doi.org/10.3390/cancers15041316 Messai Y., Gad S., Noman M., Teuff G., Couvé S., Janji B., Kammerer S., Rioux-leclerc N., Hasmim M., Ferlicot S., Baud V., Méjean A., Mole D., Richard S., Eggermont A., Albiges L., Mami-Chouaib F., Escudier B., and Chouaib S., 2016, Renal cell carcinoma programmed death-ligand 1, a new direct target of hypoxia-inducible factor-2 alpha, is regulated by von Hippel-Lindau gene mutation status, European Urology, 70(4): 623-632. https://doi.org/10.1016/j.eururo.2015.11.029 Nickerson M., Jaeger E., Shi Y., Durocher J., Mahurkar S., Zaridze D., Matveev V., Janout V., Kollarova H., Bencko V., Navratilova M., szeszenia-Dabrowska N., Mates D., Mukeria A., Holcatova I., Schmidt L., Toro J., Karami S., Hung R., Gerard G., Linehan W., Merino M., Zbar B., Boffetta P., Brennan P., Rothman N., Chow W., Waldman F., and Moore L.E., 2008, Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors, Clinical Cancer Research, 14(15): 4726-4734. https://doi.org/10.1158/1078-0432.CCR-07-4921 Ordóñez-Navadijo Á., Fuertes-Yebra E., Acosta-Iborra B., Balsa E., Elorza A., Aragonés J., Landazuri M., and Landazuri M.O., 2016, Mutant versions of von Hippel-Lindau (VHL) can protect HIF1α from SART1-mediated degradation in clear-cell renal cell carcinoma, Oncogene, 35(5): 587-594. https://doi.org/10.1038/onc.2015.113 Patard J., Rioux-Leclercq N., Masson D., Masson D., Zerrouki S., Jouan F., Collet N., Dubourg C., Lobel B., Denis M., and Fergelot P., 2009, Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma, British Journal of Cancer, 101(8): 1417-1424. https://doi.org/10.1038/sj.bjc.6605298
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==